For Physicians

At Kura Oncology, our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives, and we recognize the critical role that healthcare providers play in achieving that mission.

We believe that precision medicines represent the future of cancer treatment, offering physicians the potential for smarter, safer and more effective ways to treat cancer.

We are advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.

Our most advanced candidate is tipifarnib, a farnesyl transferase inhibitor that is currently being evaluated in multiple clinical studies, including HRAS mutant head and neck squamous cell carcinomas (HNSCC).

Our pipeline is also highlighted by KO-539, a menin inhibitor currently in a Phase 1/2A clinical trial in patients with relapsed/refractory acute myeloid leukemia.

For questions regarding our ongoing clinical studies or potential investigator-initiated research, please contact medicalaffairs@kuraoncology.com or (617) 588-3755.

You can also find more information about our programs below.

Access to Investigational Drugs Outside a Clinical Study

Kura Oncology is committed to realizing the promise of precision medicines for the treatment of cancer. To do this, we conduct clinical studies to assess the safety and efficacy of investigational drugs, and the data generated from these studies allows us to obtain the necessary approvals from Health Authorities which allow for broad access to medicines.

At Kura Oncology, we believe that wherever possible, use of an investigational drug for a patient as part of a clinical study is preferable as clinical studies can generate data that may lead to the approval of drugs and, consequently, to wider patient availability.

However, we also recognize that, when participating in a clinical study is not possible, patients facing serious or life-threatening conditions may seek access to investigational drugs outside of a clinical study setting.

Consistent with applicable laws and regulations, Kura Oncology may provide patients with access to investigational drugs through Expanded Access/Compassionate Use Programs when there is sufficient evidence of the safety profile and clinical activity of the investigational drug to support its use in a particular circumstance. The patient’s physician will perform an assessment as to the patient’s suitability for the treatment.

At this time, Kura Oncology is only providing expanded access to our investigational drug tipifarnib for eligible patients with HRAS mutations or peripheral T-Cell Lymphoma (PTCL) in the United States as permitted under local laws and regulatory requirements.

Additional information regarding access to our investigational drug tipifarnib outside of clinical studies can be found at www.clinicaltrials.gov (NCT04809233). Visit Kura Oncology Clinical Trials for specific details on our current clinical studies and, for a more general list of clinical studies currently recruiting patients, please visit www.clinicaltrials.gov.

It is important to note that the terminology used can vary from country to country and be dependent on the way that the drug is accessed. Although often referred to as Expanded Access Programs or Compassionate Use Programs, these types of access can also be known as Early Access, Emergency Use, Individual Patient Expanded Access, Named Patient Program and Treatment Protocols.

Eligibility Criteria:

All requests for access to investigational drugs outside of a clinical study will be assessed against the following criteria.

Patient Eligibility Criteria

To be eligible for access to an investigational drug outside of a clinical study, a patient must meet the following criteria:

Suffers from a serious or immediately life-threatening disease or condition.
Has exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.
Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology clinical or medically responsible individual.

Investigational Drug Criteria

In addition to the patient eligibility requirements, the investigational drug must meet the following criteria:

The drug is under investigation in one or more clinical studies.
There is sufficient evidence that the investigational drug will have an acceptable safety profile for the intended patient population.
There is biological rationale for that disease coupled with adequate human clinical data to support an assessment that the potential patient benefit justifies the potential risks of the treatment use, and those potential risks are not unreasonable in the context of the disease or condition to be treated.
The provision of the investigational drug will not interfere with or compromise the clinical development of the drug.
Adequate supply of the investigational drug exists to perform necessary clinical studies in addition to provide access to patients who do not have alternative treatment options.

Treating Physician Criteria and Responsibilities

The physician attending to the patient receiving an investigational or unlicensed drug outside of a clinical trial must be properly licensed and fully qualified to administer the drug.

The physician must agree in writing to comply with:

Any applicable country-specific legal and regulatory requirements related to providing an investigational or unlicensed drug under Expanded Access; and,
Any Kura requirements in terms of medical criteria, safety reporting, drug supply/use, and protection of intellectual property.

How to Request Access:

All requests should be submitted by a medically qualified physician, using the form below. Kura Oncology is committed to providing a fair and equitable evaluation of all the requests we receive; therefore, all decisions are based on clinical circumstances. Whenever possible, patients will be referred to ongoing clinical studies as the primary way to access investigational drugs. We will review requests on a case-by-case basis, and the fact that our treatment is made available to one patient does not guarantee it will be made available to future patients. We continually evaluate the benefit-risk profile of our investigational drugs and, based on evolving clinical data, we may require additional information from a treating physician to fully evaluate a request. We cannot guarantee that all requests for access will be granted, even when eligibility criteria are met. We regularly monitor the email box that these requests may be submitted to and we will acknowledge each submitted request within one (1) business day after receipt. You can find further contact details on the Contact Us page of our website.

The publication of this policy by Kura Oncology is not a guarantee of access to any specific investigational drug by any individual patient. Kura Oncology may revise this Expanded Access Policy at any time.

Physician Identity
Name*
First Last
Specialty*
Contact Details
Email*
Enter Email Confirm Email
Company/Hospital*
Address*
City State / Province / Region
Phone number*
Product Request
Please do not include any patient identifiers (e.g. patient name etc.)
Drug/product*
Dose/strength (if known)
Duration of Treatment (if known)
Quantity (if known)
Disease / condition to be treated*
Rationale for request*
Additional information (e.g. previously used therapies, summary of patient history. Note – please do not include any patient identifiers)
CAPTCHA

For Physicians

Access to Investigational Drugs Outside a Clinical Study

Eligibility Criteria:

How to Request Access:

Physician Identity

Contact Details

Product Request

CORPORATE HEADQUARTERS